Abstract: The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.
Type:
Grant
Filed:
April 2, 2018
Date of Patent:
September 22, 2020
Assignee:
QUARK PHARMACEUTICALS, INC.
Inventors:
Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
Abstract: The present disclosure relates to methods of treating a patient suffering from or at risk of developing an ocular disease, disorder or injury, and includes treatment regimens using a double-stranded RNA compound that down-regulates CASP2 expression, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 1, 2016
Date of Patent:
February 25, 2020
Assignee:
Quark Pharmaceuticals, Inc.
Inventors:
Shai Erlich, James D. Thompson, Rabia Ozden, Elena Feinstein
Abstract: The invention relates to modified siRNA compounds which down-regulate target gene expression, to pharmaceutical compositions comprising such compounds and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions.
Abstract: Provided herein are double stranded nucleic acid molecules, compositions comprising same and methods of use thereof for the treatment of a subject wherein expression of DDIT4 is associated with the etiology or progression of a disease or disorder in the subject. The compounds are preferably chemically synthesized and modified dsRNA molecules.
Type:
Grant
Filed:
February 15, 2017
Date of Patent:
September 24, 2019
Assignee:
Quark Pharmaceuticals, Inc.
Inventors:
Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
Abstract: The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.
Type:
Application
Filed:
April 2, 2018
Publication date:
February 7, 2019
Applicant:
QUARK PHARMACEUTICALS, INC.
Inventors:
Elena FEINSTEIN, Sharon AVKIN-NACHUM, Hagar KALINSKI, Igor METT
Abstract: Disclosed herein are double stranded RNA molecules which have been modified to exhibit one of the following, increased activity, enhanced nuclease stability, reduced off target activity and or reduced immunogenicity, to pharmaceutical compositions comprising such compounds and to methods of use. Further disclosed is a method for the synthesis of threose nucleic acid phosphoramidites and methods of use thereof.
Type:
Grant
Filed:
January 15, 2016
Date of Patent:
December 4, 2018
Assignee:
Quark Pharmaceuticals, Inc.
Inventors:
Sharon Avkin-Nachum, Elena Feinstein, Leonid Beigelman
Abstract: The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.
Abstract: The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.
Type:
Grant
Filed:
September 12, 2013
Date of Patent:
April 3, 2018
Assignee:
QUARK PHARMACEUTICALS, INC.
Inventors:
Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
Abstract: The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.
Type:
Application
Filed:
September 12, 2013
Publication date:
February 15, 2018
Applicant:
QUARK PHARMACEUTICALS, INC.
Inventors:
Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
Abstract: The invention relates to modified siRNA compounds which down-regulate target gene expression, to pharmaceutical compositions comprising such compounds and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions.
Abstract: The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.
Type:
Grant
Filed:
July 14, 2017
Date of Patent:
January 16, 2018
Assignee:
Quark Pharmaceuticals, Inc.
Inventors:
Elizabeth C. Squiers, Shai Erlich, Daniel Rothenstein, Nir Sharon, Daniel J. Odenheimer, Elena Feinstein
Abstract: Provided herein are double stranded nucleic acid molecules, compositions comprising same and methods of use thereof for the treatment of a subject wherein expression of DDIT4 is associated with the etiology or progression of a disease or disorder in the subject. The compounds are preferably chemically synthesized and modified dsRNA molecules.
Type:
Application
Filed:
February 15, 2017
Publication date:
January 11, 2018
Applicant:
Quark Pharmaceuticals Inc.
Inventors:
Elena FEINSTEIN, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
Abstract: Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising down-regulating the TLR2 gene or both the TLR2 gene and TLR4 gene.
Type:
Grant
Filed:
October 28, 2015
Date of Patent:
November 21, 2017
Assignees:
Quark Pharmaceuticals Inc., Washington University
Inventors:
Andrew E. Gelman, Elena Feinstein, Svetlana Adamsky, Igor Mett, Hagar Kalinski, Sharon Avkin-Nachum
Abstract: Disclosed herein are methods and kits useful for providing neuroprotection to neurons in the inner ear and to methods of treating inner ear diseases and disorders, including tinnitus and Mnire's disease.
Abstract: The invention relates to modified siRNA compounds which down-regulate target gene expression, to pharmaceutical compositions comprising such compounds and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions.
Abstract: The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.
Type:
Grant
Filed:
August 27, 2015
Date of Patent:
July 11, 2017
Assignee:
Quark Pharmaceuticals, Inc.
Inventors:
Elena Feinstein, Evgenia Alpert, Igor Mett, Amir Bar-Ilan, Igor Spivak, Hagar Kalinski, Natanja Slager
Abstract: The present invention provides double-stranded RNA (dsRNA) compounds comprising a sense and antisense strand, wherein at least one strand is conjugated to a moiety comprising a phenyl hydrocarbyl group, pharmaceutical compositions comprising same and uses thereof.
Abstract: Provided herein are double stranded nucleic acid molecules, compositions comprising same and methods of use thereof for the treatment of a subject wherein expression of DDIT4 is associated with the etiology or progression of a disease or disorder in the subject. The compounds are preferably chemically synthesized and modified dsRNA molecules.
Type:
Grant
Filed:
September 12, 2013
Date of Patent:
April 4, 2017
Assignee:
QUARK PHARMACEUTICALS, INC.
Inventors:
Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
Abstract: The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.
Type:
Application
Filed:
May 27, 2015
Publication date:
March 23, 2017
Applicant:
Quark Pharmaceuticals, Inc.
Inventors:
Elizabeth C. Squiers, Shai Erlich, Daniel Rothenstein, Nir Sharon, Daniel J. Odenheimer, Elena Feinstein
Abstract: The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection.
Type:
Application
Filed:
August 4, 2016
Publication date:
November 17, 2016
Applicant:
Quark Pharmaceuticals, Inc.
Inventors:
Sharon Avkin-Nachum, Elena Feinstein, Hagar Kalinski, Igor Mett